Fig. 2: 7DW8-5 has a broad antiviral activity against three different RNA viruses.

Breadth of protection conferred by 7DW8-5 (IN; 2 days before) extends to SARS-CoV-2 Omicron BA.1 and BA.5 variants in BALB/c mice (a, b) and Delta variant in K18 human-ACE2 transgenic C57BL/6 mice (c) or Syrian hamsters (d), as well as to RSV A2 strain in BALB/c mice (e) and influenza A1/H1N1/PR8 strain in C57BL/6 mice (f, g). The dose of challenge virus used is indicated at the top of each figure panel, and the number of animals used is reflected by the number of data points. The dose of 7DW8-5 given to mice was 2 µg each, whereas the dose for hamsters was 100 µg/kg. In (a, b), body weight was measured prior to and on day 3 post-viral challenge, and the infectious viral load was determined 3 days after viral challenge, as was done for (c) for both lung and nasal tissues. In (d), the viral load was determined 5 days after challenge. In (e), body weight was measured prior to and on day 2 post-viral challenge, and the lung viral load was determined 4 days after the challenge. In (f), body weight was measured prior to and on day 3 post-challenge, and the lung viral load was determined 3 days after challenge. In (g), a Kaplan–Meier survival plot is shown following a lethal influenza virus challenge. Non-parametric statistical analysis was done for all the experiments shown in (a) through (f), in Prism v 9.3, using two-tailed Mann–Whitney U test, and the results (including statistics) represent one of two independent biological experiments. Mean (black line) ± SEM is represented for each of the above graphs (a–f). The dotted lines in the TCID50/g graphs and PFU/mL graphs indicate the limit of quantitation of the viral load. A log-rank Cox–Mantel test was performed in (g) to compare the survival curves of the two groups with a hazard ratio of 10.63 between them.